SWOG clinical trial number
CTSU/A071701
GENOMICALLY-GUIDED TREATMENT TRIAL IN BRAIN METASTASES
Open
Phase
Abbreviated Title
GENOMICALLY-GUIDED TREATMENT IN BRAIN METASTASES
Status Notes
Step 0 & Step 1 Activation Effective 8/15/19; SWOG Activation Effective 9/1/19
Effective Tuesday, January 9, 2024, new patient registration (Step 1) to the entrectinib (NTRK/ROS1) cohort is closed.
Effective Tuesday, January 9, 2024, new patient registration (Step 1) to the entrectinib (NTRK/ROS1) cohort is closed.
Activated
09/01/2019
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE
Research committees
Early Therapeutics & Rare Cancers
Eligibility Criteria Expand/Collapse
Eligibility criteria are accessible from the protocol abstract page on the CTSU website (http://www.ctsu.org ).
Other Clinical Trials
SWOG Clinical Trial Number
CTSU/AOST2032
AOST2032: A Feasibility and Randomized Phase 2/3 Study of the VEFGR2/MET Inhibitor Cabozantinib in Combination with Cytotoxic Chemotherapy for Newly Diagnosed Osteosarcoma
Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
02/17/2023
Open
SWOG Clinical Trial Number
CTSU/AOST2031
AOST2031: A Phase 3 Randomized Controlled Trial Comparing Open vs Thoracoscopic Management of Pulmonary Metastases in Patients with Osteosarcoma
Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
02/15/2022
Open
SWOG Clinical Trial Number
S2012
Randomized Phase II/III Trial of First Line Platinum/Etoposide with or without Atezolizumab (NSC#783608) in Patients with Poorly Differentiated Extrapulmonary Small Cell Neuroendocrine Carcinomas (NEC)
Research Committee(s)
Early Therapeutics & Rare Cancers
Activated
12/02/2021
Accrual
34%
Open
Phase